How long does it take to experience results from L-Carnitine
Wen-Qing L et al (2015) Characterization of phenolic constituents inhibiting the formation of sulfur-containing volatiles produced during Garlic processing
CrossRef Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis Jung Hoon Cha, Na Ri Park, Sung Woo Cho, Heechul Nam, Hyun Yang, Eun Sun Jung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung, Si Hyun Bae Frontiers in Immunology .2024;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response Camilo Julio Llamoza-Torres, Mara Fuentes-Pardo, Bruno Ramos-Molina Metabolism and Target Organ Damage .2024;[Epub] CrossRef Biological and clinical role of TREM2 in liver diseases Ke Ma, Shouliang Guo, Jin Li, Tao Wei, Tingbo Liang Hepatology Communications .2024;[Epub] CrossRef 12,157 View 374 Download 15 Web of Science Crossref Special Review Steatotic liver disease Abstract PDF The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word fatty. Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD)
In addition, Fusicatenibacter and Sutterella can serve as potential biomarkers for PSO diagnosis, while Lachnospiraceae_GCA-900066575, Escherichia-Shigella, [Eubacterium]_ventriosum_group , and Lachnospiraceae_NK4A136_group have potential value in discriminating PSO disease remission
